Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer-Reference-Cited by-同舟云学术

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer

Published:2019-10-03 Issue:11 Volume:110 Page:3573-3583
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Makino Yoshinori¹²^ORCID,Makihara‐Ando Reiko¹,Ogawa Takanori²³,Sato Hitoshi²,Goto Yasushi⁴,Kanda Shintaro⁴,Horinouchi Hidehito⁴^ORCID,Fujiwara Yutaka⁴^ORCID,Ohe Yuichiro⁴^ORCID,Yamamoto Noboru⁴⁵

Affiliation:

1. Department of Pharmacy National Cancer Center Hospital Tokyo Japan

2. Division of Pharmacokinetics/Pharmacodynamics Department of Pharmacology, Toxicology, and Therapeutics School of Pharmacy Showa University Tokyo Japan

3. Certara G.K. Tokyo Japan

4. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

5. Department of Experimental Therapeutics Exploratory Oncology Research and Clinical Trial Center National Cancer Center Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14194

Reference18 articles.

1. A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II-DNA Complex

2. Chemotherapy advances in small‐cell lung cancer;Chan BA;J Thorac Dis,2013

3. Relapsed small cell lung cancer: treatment options and latest developments

4. Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

5. Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer;Thoracic Cancer;2023-03-30

2. Novel models for the prediction of drug–gene interactions;Expert Opinion on Drug Metabolism & Toxicology;2021-11-02

3. Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients;Neoplasma;2021